Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Iavarone

Showing results (101-110 of 145) with videos related to

Pageof 15
Sort By:
Cancers|November 2, 2019
Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical PracticeEdoardo G Giannini, Andrea Aglitti, Mauro Borzio, et al.
World Journal of Hepatology|September 26, 2022
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenibVíctor Sapena, Massimo Iavarone, Loreto Boix, et al.
JHEP Reports : Innovation in Hepatology|April 6, 2026
Impact of Hepatocellular Carcinoma on the risk of liver decompensation: a comparative analysis of patients with and without HCC: Role of HCC in liver decompensationAndrea Martini, Massimo Iavarone, Roberta D'Ambrosio, et al.
Gastroenterology|January 22, 2013
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosisYujin Hoshida, Augusto Villanueva, Angelo Sangiovanni, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 20, 2022
Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center studyMassimo Iavarone, Giulia Tosetti, Floriana Facchetti, et al.
Oncotarget|April 9, 2016
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS studyAndrea Casadei Gardini, Giorgia Marisi, Luca Faloppi, et al.
Cancers|July 24, 2019
<i>ANGPT2</i> and <i>NOS3</i> Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving SorafenibGiorgia Marisi, Elisabetta Petracci, Francesco Raimondi, et al.
Journal of Hepatology|June 12, 2020
High rates of 30-day mortality in patients with cirrhosis and COVID-19Massimo Iavarone, Roberta D'Ambrosio, Alessandro Soria, et al.
International Journal of Cancer|February 11, 2014
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 studyMario Scartozzi, Luca Faloppi, Gianluca Svegliati Baroni, et al.
Liver Cancer|August 20, 2021
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular CarcinomaFrancesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, et al.
Pageof 15

Showing results (101-110 of 145) with videos related to

Sort By:
Pageof 15
Cancers|November 2, 2019
Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical PracticeEdoardo G Giannini, Andrea Aglitti, Mauro Borzio, et al.
World Journal of Hepatology|September 26, 2022
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenibVíctor Sapena, Massimo Iavarone, Loreto Boix, et al.
JHEP Reports : Innovation in Hepatology|April 6, 2026
Impact of Hepatocellular Carcinoma on the risk of liver decompensation: a comparative analysis of patients with and without HCC: Role of HCC in liver decompensationAndrea Martini, Massimo Iavarone, Roberta D'Ambrosio, et al.
Gastroenterology|January 22, 2013
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosisYujin Hoshida, Augusto Villanueva, Angelo Sangiovanni, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 20, 2022
Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center studyMassimo Iavarone, Giulia Tosetti, Floriana Facchetti, et al.
Oncotarget|April 9, 2016
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS studyAndrea Casadei Gardini, Giorgia Marisi, Luca Faloppi, et al.
Cancers|July 24, 2019
<i>ANGPT2</i> and <i>NOS3</i> Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving SorafenibGiorgia Marisi, Elisabetta Petracci, Francesco Raimondi, et al.
Journal of Hepatology|June 12, 2020
High rates of 30-day mortality in patients with cirrhosis and COVID-19Massimo Iavarone, Roberta D'Ambrosio, Alessandro Soria, et al.
International Journal of Cancer|February 11, 2014
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 studyMario Scartozzi, Luca Faloppi, Gianluca Svegliati Baroni, et al.
Liver Cancer|August 20, 2021
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular CarcinomaFrancesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, et al.
Pageof 15